Patent application number | Description | Published |
20080234198 | Selective Vpac2 Receptor Peptide Agonists - The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes. | 09-25-2008 |
20080318845 | Selective Vpac2 Receptor Peptide Agonists - The present invention relates to peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes. | 12-25-2008 |
20090082276 | SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS - The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes. | 03-26-2009 |
20090118167 | Selective Vpac2 Receptor Peptide Agonists - The invention provides VPAC2R peptide agonists coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. | 05-07-2009 |
20090215981 | Glp-1 Pegylated Compounds - The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating conditions or disorders benefited by lowering blood glucose, decreasing food intake, decreasing gastric or intestinal emptying, increasing beta (β) cell population, or decreasing gastric or intestinal motility. | 08-27-2009 |
20090312236 | PEGYLATED INSULIN LISPRO COMPOUNDS - The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses. | 12-17-2009 |
20100009916 | SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS - The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes. | 01-14-2010 |
20100048460 | SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS - The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes. | 02-25-2010 |